Aptose Biosciences (NASDAQ: APTO) and Bioline RX (NASDAQ:BLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Risk & Volatility

Aptose Biosciences has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Bioline RX has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aptose Biosciences and Bioline RX, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences 0 1 3 0 2.75
Bioline RX 0 0 5 0 3.00

Aptose Biosciences currently has a consensus price target of $6.00, indicating a potential upside of 111.27%. Bioline RX has a consensus price target of $3.20, indicating a potential upside of 226.53%. Given Bioline RX’s stronger consensus rating and higher probable upside, analysts plainly believe Bioline RX is more favorable than Aptose Biosciences.

Valuation and Earnings

This table compares Aptose Biosciences and Bioline RX’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptose Biosciences N/A N/A -$14.06 million ($0.60) -4.73
Bioline RX N/A N/A -$15.84 million ($0.33) -2.97

Aptose Biosciences is trading at a lower price-to-earnings ratio than Bioline RX, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aptose Biosciences and Bioline RX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aptose Biosciences N/A -129.12% -111.84%
Bioline RX N/A -47.20% -42.23%

Insider & Institutional Ownership

0.9% of Aptose Biosciences shares are held by institutional investors. Comparatively, 36.4% of Bioline RX shares are held by institutional investors. 1.1% of Bioline RX shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bioline RX beats Aptose Biosciences on 8 of the 10 factors compared between the two stocks.

Aptose Biosciences Company Profile

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Bioline RX Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.